Latest News for: biogen

Edit

Biogen Announces Board Chair Transition

Nasdaq Globe Newswire 11 Feb 2026
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair. Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair ... .
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Biogen Inc)

Public Technologies 10 Feb 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... BIOGEN INC ... BIOGEN INC., 225 BINNEY 3 ... BIOGEN INC ... Biogen Inc.
Edit

Notice of Proposed Sale of Securities (Form 144) (Biogen Inc)

Public Technologies 09 Feb 2026
). The text version of this document is not available ... Disclaimer. Biogen Inc.
Edit

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China (Biogen Inc)

Public Technologies 09 Feb 2026
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X ...
Edit

Biogen Reports Fourth Quarter and Full Year 2025 Results (Biogen Inc)

Public Technologies 06 Feb 2026
). Stockholder Communications. Attachments Original document Permalink ... Biogen Inc.
Edit

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Wall Street Journal 06 Feb 2026
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments ... .
Edit

Q4 and Full Year 2025 Biogen Earnings Presentation (Biogen Inc)

Public Technologies 06 Feb 2026
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-), and the Biogen X ...
Edit

Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales

The Call 06 Feb 2026
Biotech company Biogen (NASDAQ ... Is now the time to buy Biogen? Find out by accessing our full research report, it’s free. Biogen (BIIB) Q4 CY2025 Highlights. ... Biogen’s demand was weak over the last five years as its sales fell at a 6% annual rate.
Edit

Biogen reports strong fourth quarter and full year 2025 results and provides full year 2026 financial guidance (Form 8-K) (Biogen Inc)

Public Technologies 06 Feb 2026
) Biogen reports strong fourth quarter and full year 2025 results and provides full year 2026 financial guidance ... Biogen Inc ... ET on February 6, 2026 and will be accessible through the Investors section of Biogen's website, www.biogen.com ... About Biogen.
Edit

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

The Call 06 Feb 2026
Biogen Inc ... The journey to these Q4 results was defined by Biogen’s aggressive "Fit for Growth" restructuring program initiated by CEO Christopher Viehbacher ... Biogen (NASDAQ ... Biogen’s Q4 results offer a masterclass in corporate reinvention.
Edit

Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse

The Call 06 Feb 2026
As of February 6, 2026, Biogen Inc ... With a significant quarterly earnings beat reported just today, the market is beginning to weigh whether the "New Biogen" is finally ready to reward patient long-term investors.
Edit

BiogenQ4 2025 Earnings Presentation FINAL (Biogen Inc)

Public Technologies 06 Feb 2026
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-), and the Biogen X ...
Edit

Q4 2025 Earnings Press Release FINAL (Biogen Inc)

Public Technologies 06 Feb 2026
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-), and the Biogen X ...
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (Biogen Inc)

Public Technologies 06 Feb 2026
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases ... Biogen's share of pre-tax profits in the U.S ... Biogen Inc.
Edit

Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings

The Call 05 Feb 2026
Biotech company Biogen (NASDAQ ... Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues of $2.53 billion, up 2.8% year on year ... Biogen has missed Wall Street’s revenue estimates twice over the last two years.

Article Search

tools
×
×
×
×